Results 161 to 170 of about 5,762,549 (184)

Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study.

Journal of Clinical Oncology
11500 Background: TGCT is a rare, locally aggressive mesenchymal neoplasm, driven by the overproduction of colony-stimulating factor 1 (CSF-1), and is often associated with joint pain, swelling, stiffness and functional impairment.
Xiaohui Niu, Vinod Ravi, Javier Martin Broto, Yong Zhou, Albiruni Ryan Abdul Razak, Ramy Saleh, Jingnan Shen, Tang Liu, Silvia Stacchiotti, Kamalesh K. Sankhala, César Serrano, Jing Wang, Yingqi Hua, Piotr Rutkowski, Xiaojing Zhang, Yi Feng, Tao Li, Giacomo Giulio Baldi, Hairong Xu, Hans Gelderblom   +19 more
openaire   +1 more source

Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.

Journal of Clinical Oncology, 2019
e18236 Background: The double-blind, randomized, placebo-controlled phase 3 ENLIVEN study in TGCT demonstrated a significant tumor response at week 25 by RECIST for pexidartinib (39% vs. 0% for placebo) and improvement in joint function and symptoms.
William D. Tap, Rebecca M Speck, Xin Ye, Emanuela Palmerini, Silvia Stacchiotti, Jayesh Desai, Andrew J. Wagner, Thierry Alcindor, Kristen N. Ganjoo, Javier Martin Broto, Qiang Wang, Dale Edward Shuster, Heather Gelhorn, Hans Gelderblom   +13 more
openaire   +1 more source

Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial.

Journal of Clinical Oncology
11567 Background: TGCT is a rare, locally-aggressive, soft-tissue tumor driven by colony-stimulating factor-1 (CSF-1) overproduction, often leading to impaired PF. Pimicotinib (pimi), an oral, highly-selective CSF-1 receptor inhibitor, demonstrated robust
Gabriel Tinoco, Vinod Ravi, Hans Gelderblom, Qingping Zou, Boyao Shan, Aimar Zhang, Niki Karachaliou, Vishal Ghori, Xiaohui Niu   +8 more
openaire   +1 more source

Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.

Journal of Clinical Oncology
11568 Background: TGCT is a rare, locally-aggressive neoplasm associated with significant morbidity and functional impairment. Colony-stimulating factor-1 receptor (CSF-1R) inhibitors are effective for unresectable TGCT, but current options may be limited
Hans Gelderblom, Vinod Ravi, Vishal Ghori, Aimar Zhang, Niki Karachaliou, Boyao Shan, Qingping Zou, Xiaohui Niu   +7 more
openaire   +1 more source

Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.

Journal of Clinical Oncology
11571 Background: TGCT is a rare, locally aggressive, soft-tissue tumor associated with significant morbidity. Pimicotinib (pimi) is an oral, highly selective, small molecule colony-stimulating factor-1 receptor (CSF-1R) inhibitor. In the Phase 3 MANEUVER
Vinod Ravi, Vishal Ghori, Aimar Zhang, Niki Karachaliou, Hans Gelderblom, Qingping Zou, Boyao Shan, Xiaohui Niu   +7 more
openaire   +1 more source

Outcomes of Tenosynovial Giant Cell Tumor of the Foot and Ankle

Foot and Ankle International, 2023
James R Barnett, Karan Malhotra, Matthew Welck   +2 more
exaly  

Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor

Human Cell, 2020
Tadashi Kondo, Kazutaka Kikuta, Rei Noguchi   +2 more
exaly  

A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis

Journal of Surgical Oncology, 2022
Sebastian Bauer, Javier Martín-Broto, Geert Spierenburg   +2 more
exaly  

Tenosynovial Giant Cell Tumor (TGCT)

2019
openaire   +1 more source

Long-term outcomes of pexidartinib in tenosynovial giant cell tumors

Cancer, 2021
William D Tap, Hans J. Gelderblom, John H. Healey   +2 more
exaly